13 Years of Excellence: Taiwan’s Premier Biologics Summit Driving Innovation Across Manufacturing, R&D & Clinical Trials

Dr. Lin is a biomedical scientist with over 20 years of experience in life science industries, spanning medical devices, pharmaceuticals, biomaterials, and biochips. He previously served as Deputy Project Director at Taiwan’s ITRI, leading global strategic alliances. As Senior VP at Body Organ Biomedical Inc., he expanded operations across Taiwan, China, and the Netherlands, establishing sales networks and securing regulatory approvals.

He led cross-border R&D collaborations, securing a €300,000 SenterNovem grant in 2009, and successfully filed 36 patents through joint research. Earlier, he also completed Taiwan's first bone filler registration. Dr. Lin holds a Ph.D. in Bioengineering from National Taiwan University and an MBA from National Chengchi University.

Dr Vivian Meng-Wei Kuo has over 16 years of in-depth experience in scientific research, technical operations, process development and validation, CMC and cGMP compliance, as well as regulatory filing and inspection from IND to BLA. She has led teams in process development, scale-up and technology transfer for more than 20 projects across clinical phases I–III to commercial stages, ranging from lab scale to 50 L, 500 L, 2000 L and 15 000 L, including multi-site coordination. She also oversaw dossier readiness and technical report preparation for IND and BLA submissions and inspections (FDA, EU, NMPA), and managed over 18 internal and CDMO projects to achieve key milestones successfully.

Dr. Chang Jia-Ming is the Chairman and General Manager of Vacino Biomedical Co., Ltd. He obtained his Ph.D. from the Institute of Biochemistry, National Taiwan University School of Medicine in 1996.

Dr. Chang has held various key positions in Taiwan’s biomedical and regulatory sectors, including Executive Director of the Institute of Drug Platform Technology at the Biotechnology Development Center, and advisory member of the Genetically Modified Food Review Committee under the Ministry of Health and Welfare (MOHW). He also serves on the Editorial Committee of the Chinese Pharmacopoeia of the Ministry of Health and Welfare, the Standard-setting Committee of the National Bureau of Standards, Ministry of Economic Affairs, and the TAF ISO Medical Laboratory Technical Review Committee.

In academia, Dr. Chang has contributed as an Adjunct Assistant Professor at several institutions, including the Institute of Pathology and Parasitology and the Institute of Medical Sciences at the National Defense Medical Center, as well as the Department of Applied Chemistry at National Chiao Tung University.

Dr. Heidi Wang is an experienced global drug development and regulatory expert with more than 30 years of Pharmaceutical Industry and Biotech experience. With expertise in oncology, virology, immunology and other therapeutic areas, Heidi led and contributed to shaping strategy and delivering approvals for Bristol Myers Squibb Company (BMS) and now, for OBI and OBIGEN.

Importantly, Heidi’s positive leadership style and inclusive mindset helped to transform company’s culture and processes to optimise their portfolio acceleration and to bring people together. Leveraging her strengths in problem solving, risk mitigation and asking the right questions, coupled with a deep expertise in drug development, Heidi is now guiding OBI, OBIGEN and as a Board member of a Taiwan-based company and her alma mater, Fu-Jen University. She also volunteers as an advisor and mentor to individuals and multiple organisations in the US, Europe and Taiwan.

Dr. Chung-Yi Wu joined CHO PHARMA as Executive Vice President in 2019, bringing over 20 years of research and development experience to strengthen the scientific foundation and elevate competitiveness of CHO PHARMA. In 2022, Dr. Wu was promoted to President, CEO and elected as a member of the Board of Directors.

Prior to CHO PHARMA, Dr. Wu served as Research Professor at the Genomic Research Center, Academia Sinica. During his tenure, he published 100+ scientific papers and was granted more than 40 patents. His impressive achievement has garnered him distinguished awards, such as the “2014 American Chemical Society David Y. Gin New Investigator Award” and “Taiwan Bio-Development Foundation Lecturer Scholar Award”.

Dr. Wu obtained his Ph.D. in Applied Chemistry from National Chiao Tung University and undertook postdoctoral research at the Scripps Research Institute, mentored by Prof. Chi-Huey Wong, a preeminent academician and a pioneer in glycosciences.